News
MIRA
0.7920
-2.98%
-0.0243
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice
TipRanks · 14h ago
Mira Pharmaceuticals risks Nasdaq delisting after shares fall below $1 bid price requirement
PUBT · 15h ago
Mira Pharmaceuticals provides update on MIRA-55, SKNY-1
TipRanks · 1d ago
Mira Pharmaceuticals advances MIRA-55 toward IND-enabling studies after completing exploratory tox dosing in rats, dogs
PUBT · 1d ago
Weekly Report: what happened at MIRA last week (0720-0724)?
Weekly Report · 5d ago
Weekly Report: what happened at MIRA last week (0713-0717)?
Weekly Report · 07/20 09:34
Weekly Report: what happened at MIRA last week (0706-0710)?
Weekly Report · 07/13 09:34
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55
TipRanks · 07/10 12:29
Mira Pharmaceuticals reports formulation results for MIRA-55
TipRanks · 07/10 12:11
MIRA Pharma Announces Results Preclinical Studies Evaluating Optimized Oral Formulations Of MIRA-55, Oral Drug Candidate Being Developed As Non-Opioid Therapy For Chronic Inflammatory Pain
Benzinga · 07/10 12:03
Mira Pharmaceuticals reports positive preclinical oral formulation results for pain drug candidate MIRA-55
PUBT · 07/10 12:03
MIRA PHARMACEUTICALS - ORAL MIRA-55 OUTPERFORMS INJECTED MORPHINE IN PRECLINICAL PAIN MODEL - SEC FILING
Reuters · 07/10 12:03
Mira Pharmaceuticals Announces Release of MIRA-55 Oral Formulation Update
PUBT · 07/10 12:01
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
Barchart · 07/10 07:00
MIRA Reports Positive Preclinical Data for SKNY-1 Program
TipRanks · 07/06 13:29
Mira Pharmaceuticals reports SKNY-1 formulation results
TipRanks · 07/06 13:20
MIRA Pharmaceuticals Reports Data From Its SKNY-1 Oral Formulation To Treat Obesity, Addiction-Related Disorders
Benzinga · 07/06 13:08
MIRA PHARMACEUTICALS - SKNY-1 SHOWS FAVORABLE BIOAVAILABILITY, ROBUST BRAIN AND LIVER EXPOSURE, ONCE-DAILY DOSING POTENTIAL - SEC FILING
Reuters · 07/06 13:01
Mira Pharmaceuticals reports positive preclinical oral formulation results for obesity, addiction drug candidate SKNY-1
PUBT · 07/06 13:00
Weekly Report: what happened at MIRA last week (0629-0703)?
Weekly Report · 07/06 09:36
More
Webull provides a variety of real-time MIRA stock news. You can receive the latest news about Mira Pharma through multiple platforms. This information may help you make smarter investment decisions.
About MIRA
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.